Diet-induced obesity predisposes anti-PD-1 antibody-treated mice to imiquimod-mediated psoriasiform dermatitis: implications for immune-related adverse events in cancer patients treated with anti-PD-1

被引：0
|
作者：
Yu, S. [1 ,2 ]
Wu, X. [2 ]
Shi, Z. [2 ]
Huynh, M. [2 ]
Hwang, S. T. [2 ]
机构：
[1] Kaohsiung Med Univ, Dept Dermatol, Kaohsiung, Taiwan
[2] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2019年 / 139卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
022
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [31] Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV
    Gay, Cynthia L.
    Bosch, Ronald J.
    McKahnn, Ashley
    Moseley, Kendall F.
    Wimbish, Chanelle L.
    Hendrickx, Steven M.
    Messer, Michael
    Furlong, Maureen
    Campbell, Danielle M.
    Jennings, Cheryl
    Benson, Constance
    Overton, Edgar T.
    Macatangay, Bernard J. C.
    Kuritzkes, Daniel R.
    Miller, Elizabeth
    Tressler, Randall
    Eron, Joseph J.
    Hardy, William David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 87 (05) : E234 - E236
  • [32] Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
    Eigentler, Thomas K.
    Hassel, Jessica C.
    Berking, Carola
    Aberle, Jens
    Bachmann, Oliver
    Gruenwald, Viktor
    Kaehler, Katharina C.
    Loquai, Carmen
    Reinmuth, Niels
    Steins, Martin
    Zimmer, Lisa
    Sendl, Anna
    Gutzmer, Ralf
    CANCER TREATMENT REVIEWS, 2016, 45 : 7 - 18
  • [33] Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Wang, Peng-Fei
    Chen, Yang
    Song, Si-Ying
    Wang, Ting-Jian
    Ji, Wen-Jun
    Li, Shou-Wei
    Liu, Ning
    Yan, Chang-Xiang
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [34] Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
    Vinnakota, Janaki Manoja
    Adams, Rachael C.
    Athanassopoulos, Dimitrios
    Schmidt, Dominik
    Biavasco, Francesca
    Zaehringer, Alexander
    Erny, Daniel
    Schwabenland, Marius
    Langenbach, Marlene
    Wenger, Valentin
    Salie, Henrike
    Cook, James
    Mossad, Omar
    Andrieux, Geoffroy
    Dersch, Rick
    Rauer, Sebastian
    Duquesne, Sandra
    Monaco, Gianni
    Wolf, Phillipp
    Blank, Thomas
    Haene, Philipp
    Greter, Melanie
    Becher, Burkhard
    Henneke, Philipp
    Pfeifer, Dietmar
    Blazar, Bruce R.
    Duyster, Justus
    Boerries, Melanie
    Koehler, Natalie
    Chhatbar, Chintan M.
    Bengsch, Bertram
    Prinz, Marco
    Zeiser, Robert
    SCIENCE TRANSLATIONAL MEDICINE, 2024, 16 (751)
  • [35] Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy
    Knight, Andrew David
    Karapetyan, Lilit
    Bruno, Sabrina
    Abushukair, Hassan Mohammed
    Bo, Na
    Wang, Hong
    Sander, Cindy
    Kirkwood, John M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
    Huang, Yiqing
    Soon, Yu Yang
    Aminkeng, Folefac
    Tay, Sen Hee
    Ang, Yvonne
    Kee, Adrian C. L.
    Goh, Boon Cher
    Wong, Alvin S. C.
    Soo, Ross A.
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (04) : 636 - 644
  • [37] Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients
    Huang, Y.
    Soon, Y. Y.
    Aminkeng, F.
    Tay, S. H.
    Ang, Y.
    Goh, B. C.
    Wong, A.
    Soo, R. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S577 - S577
  • [38] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [39] Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden
    Bomze, David
    Ali, Omar Hasan
    Bate, Andrew
    Flatz, Lukas
    JAMA ONCOLOGY, 2019, 5 (11) : 1633 - 1635
  • [40] Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer
    Toi, Y.
    Sugawara, S.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Sugisaka, J.
    Shimizu, H.
    Ono, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S598 - S599
12345